CIK: 0001281446
Total reported value
$435.1M
Reporting period: 2026-03-31 · Number of holdings: 42
GREAT POINT PARTNERS LLC disclosed 42 holdings in its latest 13F filing for the period ending 2026-03-31, with total reported value of $435.1M and a quarterly turnover rate of 92.7%.
Browse other institutions with $100M to $1B AUMBrowse other institutions starting with "G"
Great Point Partners LLC's disclosed holdings carry a Herfindahl concentration index of 0.038 — mathematically equivalent to about 26 equally-sized positions, close to its 42 actual disclosed holdings. Value is spread relatively evenly across the portfolio rather than concentrated in a handful of names.
Position sizes are fairly uniform across the portfolio (a coefficient of variation of 0.79), suggesting a disciplined, rules-based approach to how much capital goes into each idea.
No strong tilt toward either adding to existing winners or initiating outsized new positions was observed in the latest reported quarter.
Sector classification currently covers about 6% of this portfolio's disclosed value; the remainder includes holdings (e.g. unmapped tickers, options, or other security types) not yet covered by our sector mapping.
Trim IMVT
-27.3% -$5.5M
Add NKTR
+50.2% $13.9M
Trim APGE
0.0% $3.3M
Add VOR
+27.7% $13.3M
Trim AMLX
0.0% $3.2M
Trim CGEM
-52.7% -$2.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | APGE | Apogee Therapeutics INC | Stock-Other | 7.23% | -1.92% | — | |
| 2 | VOR | Vor Biopharma INC | Stock-Other | 7.18% | +1.37% | +27.73% | |
| 3 | ✓ | Zura Bio LTD | Stock-Other | 5.77% | -0.71% | +10.48% | |
| 4 | AMLX | Amylyx Pharmaceuticals INC | Stock-Other | 5.59% | -1.26% | — | |
| 5 | IBRX | Immunitybio INC | Stock-Healthcare | 5.29% | +5.29% | NEW | |
| 6 | NKTR | Nektar Therapeutics | Stock-Other | 5.23% | +2.34% | +50.17% | |
| 7 | ✓ | Stock-Other | 5.00% | +5.00% | NEW | ||
| 8 | ALMS | Alumis INC | Stock-Other | 4.33% | +4.33% | NEW | |
| 9 | DRUG | Bright Minds Biosciences INC | Stock-Other | 3.69% | +3.69% | NEW | |
| 10 | ANNX | Annexon INC | Stock-Other | 3.18% | +3.18% | NEW | |
| 11 | 4XC1 | Kalvista Pharmaceuticals INC | Stock-Other | 3.12% | -0.47% | -1.55% | |
| 12 | IMVT | Immunovant INC | Stock-Other | 3.11% | -3.07% | -27.25% | |
| 13 | JBIO | Jade Biosciences INC | Stock-Other | 3.11% | -0.92% | +19.62% | |
| 14 | CTNM | Contineum Therapeutics Inc-a | Stock-Other | 2.40% | -0.56% | +0.02% | |
| 15 | ZBIO | Zenas Biopharma INC | Stock-Other | 2.35% | +2.35% | NEW | |
| 16 | NGNE | Neurogene INC | Stock-Other | 2.32% | -0.02% | +42.86% | |
| 17 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 2.14% | +2.14% | NEW | |
| 18 | CLYM | Climb Bio INC | Stock-Other | 2.10% | +0.83% | +36.20% | |
| 19 | ORKA | Oruka Therapeutics INC | Stock-Other | 2.07% | +0.27% | — | |
| 20 | EPRX | Eupraxia Pharmaceuticals INC | Stock-Other | 2.00% | -0.94% | — | |
| 21 | VERA | Vera Therapeutics INC | Stock-Other | 1.84% | +1.84% | NEW | |
| 22 | EVMN | Evommune INC | Stock-Other | 1.72% | -0.08% | — | |
| 23 | LBRX | Lb Pharmaceuticals INC | Stock-Other | 1.70% | +1.70% | NEW | |
| 24 | CMPX | Compass Therapeutics INC | Stock-Other | 1.64% | +1.64% | NEW | |
| 25 | SCYXEUR | Scynexis INC | Stock-Other | 1.59% | +1.59% | NEW | |
| 26 | PALI | Palisade Bio INC | Stock-Other | 1.37% | +1.37% | NEW | |
| 27 | CNTX | Context Therapeutics INC | Stock-Other | 1.35% | -0.88% | -52.21% | |
| 28 | RLMD | Relmada Therapeutics INC | Stock-Other | 1.35% | +1.35% | NEW | |
| 29 | SLN | Silence Therapeutics Plc-adr | Stock-Other | 1.24% | -0.35% | +26.29% | |
| 30 | UNCY | Unicycive Therapeutics INC | Stock-Other | 1.20% | -0.29% | — | |
| 31 | TENX | Tenax Therapeutics INC | Stock-Other | 1.20% | +1.20% | NEW | |
| 32 | PMN | Promis Neurosciences INC | Stock-Other | 1.08% | +1.08% | NEW | |
| 33 | CGEM | Cullinan Therapeutics INC | Stock-Other | 0.98% | -1.15% | -52.68% | |
| 34 | IMMX | Immix Biopharma INC | Stock-Other | 0.73% | +0.73% | NEW | |
| 35 | RZLT | Rezolute INC | Stock-Other | 0.67% | -0.06% | — | |
| 36 | PHVS | Pharvaris N.V. | Stock-Other | 0.54% | -0.20% | — | |
| 37 | HUMA | Humacyte INC | Stock-Other | 0.52% | +0.52% | NEW | |
| 38 | GALT | Galectin Therapeutics INC | Stock-Other | 0.51% | +0.51% | NEW | |
| 39 | AVTX | Avalo Therapeutics INC | Stock-Other | 0.43% | -0.30% | — | |
| 40 | ALKS | Alkermes plc | Stock-Healthcare | 0.41% | +0.41% | NEW | |
| 41 | AVXL | Anavex Life Sciences CORP | Stock-Other | 0.37% | +0.37% | NEW | |
| 42 | IRD | Opus Genetics INC | Stock-Other | 0.34% | +0.34% | NEW |
Performance for Q3 2026
+17.8%
Performance Last 4 Quarters
+104.9%
Based on 69% of reported portfolio value with available pricing
| Period | Holdings | Total value | Stability | Top holdings |
|---|---|---|---|---|
| 2026-03-31 | 42 | $435.1M | 93 | |
| 2025-12-31 | 29 | $308.4M | 100 | |
| 2025-09-30 | 30 | $242.5M | 100 | |
| 2025-06-30 | 26 | $153.8M | 0 | |
| 2025-03-31 | 32 | $188.8M | 100 | |
| 2024-12-31 | 26 | $212.2M | 0 | |
| 2024-09-30 | 30 | $339.8M | 0 | |
| 2024-06-30 | 33 | $522.0M | 0 | |
| 2024-03-31 | 35 | $641.6M | 0 | |
| 2023-12-31 | 34 | $586.7M | 0 | |
| 2023-09-30 | 42 | $549.0M | 0 | |
| 2023-06-30 | 40 | $510.8M | 0 | |
| 2023-03-31 | 44 | $509.3M | 0 | |
| 2022-12-31 | 42 | $510.2M | 0 | |
| 2022-09-30 | 40 | $415.3M | 0 | |
| 2022-06-30 | 35 | $417.0M | 0 | |
| 2022-03-31 | 30 | $413.8M | 0 | |
| 2021-12-31 | 36 | $450.1M | 0 | |
| 2021-09-30 | 36 | $429.5M | 0 | |
| 2021-06-30 | 30 | $476.7M | 68 | |
| 2021-03-31 | 28 | $483.9M | 86 | |
| 2020-12-31 | 33 | $615.7M | 100 | |
| 2020-09-30 | 34 | $1.1B | 49 | |
| 2020-06-30 | 36 | $1.3B | 75 | |
| 2020-03-31 | 36 | $957.1M | 64 | |
| 2019-12-31 | 37 | $1.1B | 100 | |
| 2019-09-30 | 43 | $1.1B | 56 | |
| 2019-06-30 | 31 | $900.8M | 90 | |
| 2019-03-31 | 41 | $1.0B | 66 | |
| 2018-12-31 | 42 | $791.2M | 77 | |
| 2018-09-30 | 30 | $641.7M | 64 | |
| 2018-06-30 | 44 | $721.6M | 82 | |
| 2018-03-31 | 38 | $673.4M | 77 | |
| 2017-12-31 | 39 | $586.1M | 85 | |
| 2017-09-30 | 39 | $514.0M | 71 | |
| 2017-06-30 | 41 | $558.2M | 67 | |
| 2017-03-31 | 39 | $503.5M | 79 | |
| 2016-12-31 | 35 | $486.8M | 51 | |
| 2016-09-30 | 35 | $392.1M | 79 | |
| 2016-06-30 | 39 | $349.2M | 76 | |
| 2016-03-31 | 33 | $278.7M | 53 | |
| 2015-12-31 | 25 | $238.3M | 55 | |
| 2015-09-30 | 37 | $252.8M | 67 | |
| 2015-06-30 | 34 | $256.5M | 88 | |
| 2015-03-31 | 35 | $227.2M | 75 | |
| 2014-12-31 | 28 | $207.8M | 93 | |
| 2014-09-30 | 40 | $232.8M | 70 | |
| 2014-06-30 | 38 | $224.8M | 70 | |
| 2014-03-31 | 38 | $191.5M | 88 | |
| 2013-12-31 | 29 | $141.6M | 92 | 144915N269562K336106P |
| 2013-09-30 | 32 | $144.1M | 0 | 144915N236106P302318X |
Great Point Partners LLC's most significant position changes for 2026-03-31: New buy: Immunitybio INC (IBRX); New buy: ; Sold out: Disc Medicine INC (IRON); Sold out: Rapt Therapeutics INC (RAPT); New buy: Alumis INC (ALMS).
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | NKTR | Nektar Therapeutics | +2.3% | +50.17% | Add |
| 2 | VOR | Vor Biopharma INC | +1.4% | +27.73% | Add |
| 3 | CLYM | Climb Bio INC | +0.8% | +36.20% | Add |
| 4 | ORKA | Oruka Therapeutics INC | +0.3% | — | Unchanged |
| 5 | NGNE | Neurogene INC | 0% | +42.86% | Add |
| 6 | RZLT | Rezolute INC | -0.1% | — | Unchanged |
| 7 | EVMN | Evommune INC | -0.1% | — | Unchanged |
| 8 | PHVS | Pharvaris N.V. | -0.2% | — | Unchanged |
| 9 | UNCY | Unicycive Therapeutics INC | -0.3% | — | Unchanged |
| 10 | AVTX | Avalo Therapeutics INC | -0.3% | — | Unchanged |
| 11 | SLN | Silence Therapeutics Plc-adr | -0.4% | +26.29% | Add |
| 12 | 4XC1 | Kalvista Pharmaceuticals INC | -0.5% | -1.55% | Trim |
| 13 | CTNM | Contineum Therapeutics Inc-a | -0.6% | +0.02% | Add |
| 14 | ✓ | Zura Bio LTD | -0.7% | +10.48% | Add |
| 15 | CNTX | Context Therapeutics INC | -0.9% | -52.21% | Trim |
| 16 | JBIO | Jade Biosciences INC | -0.9% | +19.62% | Add |
| 17 | EPRX | Eupraxia Pharmaceuticals INC | -0.9% | — | Unchanged |
| 18 | CGEM | Cullinan Therapeutics INC | -1.2% | -52.68% | Trim |
| 19 | AMLX | Amylyx Pharmaceuticals INC | -1.3% | — | Unchanged |
| 20 | APGE | Apogee Therapeutics INC | -1.9% | — | Unchanged |
| 21 | IMVT | Immunovant INC | -3.1% | -27.25% | Trim |
| 22 | IBRX | Immunitybio INC | — | NEW | New buy |
| 23 | ✓ | — | NEW | New buy | |
| 24 | IRON | Disc Medicine INC | — | EXIT | Sold out |
| 25 | RAPT | Rapt Therapeutics INC | — | EXIT | Sold out |
| 26 | ALMS | Alumis INC | — | NEW | New buy |
| 27 | SLNOEUR | Soleno Therapeutics INC | — | EXIT | Sold out |
| 28 | DRUG | Bright Minds Biosciences INC | — | NEW | New buy |
| 29 | DNTH | Dianthus Therapeutics INC | — | EXIT | Sold out |
| 30 | ANNX | Annexon INC | — | NEW | New buy |
| 31 | ZBIO | Zenas Biopharma INC | — | NEW | New buy |
| 32 | MLTX | Moonlake Immunotherapeutics | — | NEW | New buy |
| 33 | FULC | Fulcrum Therapeutics INC | — | EXIT | Sold out |
| 34 | UPB | Upstream Bio INC | — | EXIT | Sold out |
| 35 | VERA | Vera Therapeutics INC | — | NEW | New buy |
| 36 | LBRX | Lb Pharmaceuticals INC | — | NEW | New buy |
| 37 | CMPX | Compass Therapeutics INC | — | NEW | New buy |
| 38 | SCYXEUR | Scynexis INC | — | NEW | New buy |
| 39 | RARE | Ultragenyx Pharmaceutical In | — | EXIT | Sold out |
| 40 | PALI | Palisade Bio INC | — | NEW | New buy |
| 41 | RLMD | Relmada Therapeutics INC | — | NEW | New buy |
| 42 | TENX | Tenax Therapeutics INC | — | NEW | New buy |
| 43 | PMN | Promis Neurosciences INC | — | NEW | New buy |
| 44 | IMMX | Immix Biopharma INC | — | NEW | New buy |
| 45 | SANA | Sana Biotechnology INC | — | EXIT | Sold out |
| 46 | HUMA | Humacyte INC | — | NEW | New buy |
| 47 | GALT | Galectin Therapeutics INC | — | NEW | New buy |
| 48 | ALKS | Alkermes plc | — | NEW | New buy |
| 49 | AVXL | Anavex Life Sciences CORP | — | NEW | New buy |
| 50 | IRD | Opus Genetics INC | — | NEW | New buy |
| Period | Filed | Type | EDGAR |
|---|---|---|---|
| 2026-03-31 | 2026-05-15 | 13F-HR | View on EDGAR |
| 2025-12-31 | 2026-02-17 | 13F-HR | View on EDGAR |
| 2025-09-30 | 2025-11-14 | 13F-HR | View on EDGAR |
| 2025-06-30 | 2025-08-14 | 13F-HR | View on EDGAR |
| 2025-03-31 | 2025-05-15 | 13F-HR | View on EDGAR |
| 2024-12-31 | 2025-02-14 | 13F-HR | View on EDGAR |
| 2024-09-30 | 2024-11-13 | 13F-HR | View on EDGAR |
| 2024-06-30 | 2024-08-14 | 13F-HR | View on EDGAR |
| 2024-03-31 | 2024-05-15 | 13F-HR | View on EDGAR |
| 2023-12-31 | 2024-02-14 | 13F-HR | View on EDGAR |
| 2023-09-30 | 2023-11-14 | 13F-HR | View on EDGAR |
| 2023-06-30 | 2023-08-14 | 13F-HR | View on EDGAR |
| 2023-03-31 | 2023-05-15 | 13F-HR | View on EDGAR |
| 2022-12-31 | 2023-02-14 | 13F-HR | View on EDGAR |
| 2022-09-30 | 2022-11-14 | 13F-HR | View on EDGAR |
| 2022-06-30 | 2022-08-15 | 13F-HR | View on EDGAR |
| 2022-03-31 | 2022-05-16 | 13F-HR | View on EDGAR |
| 2021-12-31 | 2022-02-14 | 13F-HR | View on EDGAR |
| 2021-09-30 | 2021-11-15 | 13F-HR | View on EDGAR |
| 2021-06-30 | 2021-08-16 | 13F-HR | View on EDGAR |
| 2021-03-31 | 2021-05-17 | 13F-HR | View on EDGAR |
| 2020-12-31 | 2021-02-16 | 13F-HR | View on EDGAR |
| 2020-09-30 | 2020-11-16 | 13F-HR | View on EDGAR |
| 2020-06-30 | 2020-08-14 | 13F-HR | View on EDGAR |
| 2020-03-31 | 2020-05-15 | 13F-HR | View on EDGAR |
| 2019-12-31 | 2020-02-14 | 13F-HR | View on EDGAR |
| 2019-09-30 | 2019-11-15 | 13F-HR | View on EDGAR |
| 2019-06-30 | 2019-08-14 | 13F-HR | View on EDGAR |
| 2019-03-31 | 2019-05-14 | 13F-HR | View on EDGAR |
| 2018-12-31 | 2019-02-15 | 13F-HR | View on EDGAR |
| 2018-09-30 | 2018-11-14 | 13F-HR | View on EDGAR |
| 2018-06-30 | 2018-08-14 | 13F-HR | View on EDGAR |
| 2018-03-31 | 2018-05-14 | 13F-HR | View on EDGAR |
| 2017-12-31 | 2018-02-14 | 13F-HR | View on EDGAR |
| 2017-09-30 | 2017-11-14 | 13F-HR | View on EDGAR |
| 2017-06-30 | 2017-08-14 | 13F-HR | View on EDGAR |
| 2017-03-31 | 2017-05-15 | 13F-HR | View on EDGAR |
| 2016-12-31 | 2017-02-14 | 13F-HR | View on EDGAR |
| 2016-09-30 | 2016-11-14 | 13F-HR | View on EDGAR |
| 2016-06-30 | 2016-08-15 | 13F-HR | View on EDGAR |
| 2016-03-31 | 2016-05-16 | 13F-HR | View on EDGAR |
| 2015-12-31 | 2016-02-16 | 13F-HR | View on EDGAR |
| 2015-09-30 | 2015-11-16 | 13F-HR | View on EDGAR |
| 2015-06-30 | 2015-08-14 | 13F-HR | View on EDGAR |
| 2015-03-31 | 2015-05-15 | 13F-HR | View on EDGAR |
| 2014-12-31 | 2015-02-17 | 13F-HR | View on EDGAR |
| 2014-09-30 | 2014-11-14 | 13F-HR | View on EDGAR |
| 2014-06-30 | 2014-08-14 | 13F-HR | View on EDGAR |
| 2014-03-31 | 2014-05-15 | 13F-HR | View on EDGAR |
| 2013-12-31 | 2014-02-14 | 13F-HR | View on EDGAR |
| 2013-09-30 | 2013-11-14 | 13F-HR | View on EDGAR |
Institutions with a similar AUM
CIK 0001750852
Total reported value
$435.1M
124 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001867040
Total reported value
$435.1M
3 stks
2026-03-31
AUM within 0.0% of this institution
CIK 0001903320
Total reported value
$435.2M
70 stks
2024-03-31
Stale — no recent filing
AUM within 0.0% of this institution
Institutions with overlapping top holdings
CIK 0000019481
Total reported value
$362.5M
450 stks
2026-03-31
1 of the top 5 holdings overlap, including Immunitybio INC
CIK 0000078003
Total reported value
$238.8M
21 stks
2026-03-31
1 of the top 5 holdings overlap
CIK 0001596468
Total reported value
$442.5M
115 stks
2026-03-31
1 of the top 5 holdings overlap, including Amylyx Pharmaceuticals INC